Lymphatic Leukemia; Age Incidence, Duration, and Benefit Derived from Irradiation

G, Minot; Isaacs, Raphael

doi:10.1056/nejm192407031910101

Cited by 114 publications

(45 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The male predominance in our series has been noted by some (Minot et al, 1924;Hoffman & Craver, 1931;Wintrobe & Hasenbush, 1939;Pascucci, 1942;Diamond & Craver, 1951;Shimkin et al, 1951) but not all authors (Scott, 1957;Hambly & Robertson, 1959;Spiers et al, 1977;Thompson & Stainsby, 1982). Fatigue, weight loss, splenic discomfort, and sweats were common presenting symptoms.…”

Section: Discussionsupporting

confidence: 67%

Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16‐year period

1997

View full text Add to dashboard Cite

Summary.To determine major presenting features of chronic myeloid leukaemia (CML) in current practice, we have reviewed the records of 430 patients with CML referred to the Hammersmith Hospital for allogeneic bone marrow transplantation since 1981. Approximately 20% of cases were diagnosed incidentally. Symptoms such as fatigue and weight loss were associated with greater degrees of leucocytosis and splenomegaly and lower haemoglobin levels. Most bleeding patients had normal or elevated platelet counts, suggesting that platelet dysfunction was the primary cause of haemorrhage.Although thrombocytosis was common, thrombosis was not seen. Male patients and the relatively young presented with higher WBC counts and larger spleens. The reason that these groups were diagnosed with more advanced leukaemia is not clear. Although retrospective and limited to a select group of relatively young patients, this is the largest series to be reported on CML at diagnosis, and the first such report in modern clinical practice.

show abstract

Section: Discussionsupporting

confidence: 67%

Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16‐year period

1997

View full text Add to dashboard Cite

show abstract

“…22,23 Following Rö ntgen's discovery of X-rays in 1895, experimental X-ray treatments led to some very short-term suppression of tumors and tumor shrinkage, but with no reported improvement in prognosis. Furthermore, there was no evidence that these novel radiation therapies had any useful effects on acute leukemias, 24 which continued to be 'insidious, rapid, and progressive' 25 and rapidly fatal. 26,27 Between 1926 and 1947, only 3 of 150 adult and pediatric patients with acute leukemias treated at New York's Memorial Hospital survived for a year, and none lived beyond 14 months.…”

Section: White Bloodmentioning

confidence: 99%

Observations of unprecedented remissions following novel treatment for acute leukemia in children in 1948

Spain

Kadan‐Lottick

2012

J R Soc Med

View full text Add to dashboard Cite

“…In chronic myeloid leukemia amelioration of symptoms, decrease in spleen size, decreases in white blood cell count (WBC), and a shift to an increased percentage of mature myeloid cells in the peripheral blood have been well documented in patients treated with 32 P. However, the life expectancy was not substantially different than achieved in the 1920s with X-radiation (17,31). The development of cancer chemotherapeutic drugs together with the requirement for a license to obtain and use 32 P made it a therapy of the past in the chronic leukemias.…”

Section: Chronic Myeloid Leukemiamentioning

confidence: 99%

Treatment of the myeloproliferative disorders with ³²P

Berlin

2000

European J of Haematology

View full text Add to dashboard Cite

: The use of radioactive phosphorus (32P) to treat the myeloproliferative disorders (chronic leukemia, polycythemia vera and essential thrombocythemia) began in 1939 when John H. Lawrence treated the first patient on the basis of work done in the laboratory anima that found localization of the radioisotope in the spleen, liver, bone and in leukemic cells sufficient to indicate a therapeutic potential. After World War II when 32P became widely available, it was used extensively to treat the chronic leukemias and polycythemia vera. Its use in the treatment of essential thrombocythemia began later in 1950. Today it is not widely used in the treatment of the chronic leukemia, if at all, its use in polycythemia vera appears to have decreased substantially and replaced by hydroxyurea, and its use in the management of essential thrombocythemia is not widespread. In each instance it has been replaced by a drug developed for use in cancer chemotherapy, and in some instances by interferon. It probably has wider use in polycythemia vera in the rest of Western Europe than in the UK, and there are cogent reasons to suggest that it may be the best tool for the treatment of polycythemia vera. Thus have we discarded a treatment modality that in polycythemia vera may be the best?

show abstract

Lymphatic Leukemia; Age Incidence, Duration, and Benefit Derived from Irradiation

Cited by 114 publications

References 2 publications

Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16‐year period

Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16‐year period

Observations of unprecedented remissions following novel treatment for acute leukemia in children in 1948

Treatment of the myeloproliferative disorders with ³²P

Contact Info

Product

Resources

About

Lymphatic Leukemia; Age Incidence, Duration, and Benefit Derived from Irradiation

Cited by 114 publications

References 2 publications

Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16‐year period

Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16‐year period

Observations of unprecedented remissions following novel treatment for acute leukemia in children in 1948

Treatment of the myeloproliferative disorders with 32P

Contact Info

Product

Resources

About

Treatment of the myeloproliferative disorders with ³²P